Rigetti Computing, Inc.
RGTI is pricing in a quantum-commercialization outcome far ahead of its current revenue base, and the gap between $4.7B equity value and $5.1M quarterly revenue remains too wide to justify at 390.78x sales.
The market is still capitalizing Rigetti as if technical progress will convert into durable commercial revenue on a fairly short path. The actual numbers do not support that view yet. FY2025 revenue was down 27.0%, EPS was -0.70, and operating margin worsened to -798.7%. Even after a better Q2, the company produced only $5.1M of revenue and -$0.05B of EBITDA. That is not a scaling software business with latent margin, it is a hardware and research-intensive platform still searching for repeatable commercial demand.
The bullish case is not hard to see. Rigetti has $541.3M of cash, virtually no debt, improving gross margin at 43%, an expected $8.4M Q4 system revenue event, and a credible technical roadmap centered on 108 qubits now and 1,000 qubits in roughly 3 years. Those are meaningful milestones. But the stock at $4.7B already assumes that roadmap turns into a much larger installed base, stronger utilization, and eventually software or services leverage. That leap has not happened. Revenue is still described by management as lumpy, tied to installations, government projects, and acceptance testing. Investors are paying today for a business model that is still mostly aspirational.
The key debate is not whether Rigetti survives. It probably does, given the cash balance and no-debt structure. The debate is whether the equity value leaves room for error. At 390.78x sales versus peer average 2.6x, it plainly does not. The Department of Commerce opportunity for up to $100M over 3 years could help, but it is non-definitive and would include equity issuance. That is support for the balance sheet and roadmap, not proof of attractive shareholder returns from this price.
Conviction is high because the setup is asymmetric in the wrong direction for new buyers. The stock is already -73.5% from its $56.34 high and 23.2% below the 200-day average of $19.44, which means plenty of air has come out, but not enough relative to fundamentals. A more durable long case would require one of two things: sustained annual revenue growth large enough to make today's market cap defensible, or a materially lower share price that better reflects pre-profit, milestone-driven commercialization risk.
Management secures part of the up to $100M funding package, hits the 99.5% fidelity target on Cepheus-1-108Q, and the market rewards a clearer path to 2027 commercial deployments.
Rigetti delivers the $8.4M Q4 order, keeps technical milestones broadly on track, but investors balance runway strength against still-extreme valuation and weak earnings power.
Q4 C-DAC slips or is partially recognized, CHIPS-related funding stays non-definitive, and the market rerates the stock toward a lower speculative premium as losses stay above revenue by a wide margin.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 3 buy / 0 hold / 0 sell) — resolve explicitly.
Never, ever invest in the present.
Forward earnings power is still too remote to support this valuation. Trailing P/E is N/A, and even a forward P/E framework is not useful because the business remains loss-making with FY2025 EPS of -$0.70 and Q2 operating loss of $28.1M. The moat today is mostly technical know-how in superconducting architectures, fab capability, and early system deployments, but over the next 3 to 5 years that moat faces stronger-capitalized rivals and a race where AI helps quantum design and control, yet also raises the bar by making classical alternatives better and cheaper. AI is an indirect enabler for discovery workloads, but it does not make Rigetti's near-term revenue model less lumpy or its commercialization timeline shorter.
- 390.78x P/S versus peer average 2.6x leaves no valuation support if commercialization slips even one or two system deliveries.
- Q2 2026 revenue of $5.1M and expected $8.4M C-DAC recognition in Q4 show progress, but annualized revenue still sits far below what a $4.7B market cap requires.
- $541.3M cash and no debt remove near-term solvency risk, but they do not solve the core issue of -1023.9% Q2 EBITDA margin and still-negative earnings power.
- $541.3M cash with debt/equity 0.01 gives Rigetti unusually strong runway for a pre-scale quantum company and sharply lowers financing stress near term.
- Q2 2026 revenue rose to $5.1M from $1.8M and gross margin improved to 43% from 31%, helped by Novera QPU sales and better contract mix.
- Management still expects to recognize the $8.4M C-DAC order in Q4 2026, and remains on track for 3 system deliveries in 2026, giving at least one concrete near-term revenue step-up.
- The roadmap remains ambitious but specific: Cepheus-1-108Q targeting roughly 99.5% 2-qubit gate fidelity later in 2026, then 1,000 qubits, 99.9% fidelity, and gate speed below 40 ns in roughly 3 years.
- FY2025 revenue was $0.0B, down 27.0% YoY, while the stock commands a $4.7B market cap and 390.78x sales, a mismatch that leaves little room for delay.
- Profitability moved the wrong way in FY2025, with operating margin at -798.7% versus -634.9% prior year and net margin at -1494.0%, showing scale benefits are still absent.
- Q2 EBITDA was -$0.05B on just $0.01B revenue, an EBITDA margin of -1023.9%, and operating loss widened to $28.1M as R&D, infrastructure, and stock comp increased.
- The most material outside funding lever is still uncertain: Department of Commerce support is only up to $100M over 3 years, remains non-definitive, and would include equity issuance.
| Metric | Value | Context |
|---|---|---|
| Current price | $14.93 | Reference price for rating and scenario framework |
| Quant price target | $15.26 | High confidence, 2.2% above current, basis: sales_quality_blend |
| Market cap | $4.7B | Large equity value relative to current revenue base |
| FY2025 revenue | $0.0B | -27.0% YoY, still subscale on disclosed annual basis |
| FY2025 EPS | -$0.70 | Loss-making, 44.7% YoY |
| FY2025 operating margin | -798.7% | Worsened from -634.9% prior FY |
| Valuation | P/S 390.78x | P/B 9.71x | P/E N/A | P/S far above peer average 2.6x, peer avg P/E 24.8x |
| Balance sheet | Debt/Equity 0.01 | Current ratio 3.94 | Total debt $0.0B | Very strong liquidity, minimal leverage |
| Q2 2026 revenue and margin | $5.1M revenue | 43% gross margin | Up from $1.8M and 31% y/y, helped by Novera QPU sales |
| Q2 2026 EBITDA | -$0.05B | Implied EBITDA margin -1023.9% |
| Cash and runway | $541.3M cash | No debt, supports elevated 2026 CapEx and roadmap execution |
| Price action | -11.87% 1W | -31.42% 3M | -73.5% vs 52-week high | Now 23.2% below 200-day average of $19.44 |
The biggest risk to the bearish call is that a combination of $8.4M Q4 delivery, additional 2027 system wins, and a definitive up to $100M government award causes investors to look through today's 390.78x sales valuation for longer than fundamentals justify.
The next catalyst is November 9, 2026 earnings, specifically whether Rigetti actually recognizes the $8.4M C-DAC revenue and whether management converts the non-definitive government funding discussions into a signed award.
Ownership is meaningful but not especially sticky, with the top 3 institutions holding 46.3% and insiders only 0.9%. Short interest is high at 18.00%, or 58,969,224 shares, though days-to-cover is only 1.4, which means squeeze risk exists but is less structurally powerful than the headline short figure suggests. Options positioning is in a negative gamma regime with zero-gamma at $15.62, which can amplify downside volatility if the stock remains below that level.
Q2 2026 growth was driven by on-premises Novera QPU sales and recognition of previously announced purchase orders.
Revenue remains tied to milestone-based deliveries, with the $8.4M C-DAC system in India expected in Q4 2026 and the HPE/PSC 9-qubit system targeted for 2027.
International exposure is visible through the India C-DAC order, but the company does not provide a geographic revenue split in the supplied data.
Rigetti reiterated a 3-year path to quantum advantage while Q4 revenue is set up by C-DAC delivery.
Execution has been mixed. On the positive side, management said in 2024 Q3 that liquidity should last until midway through Q1 2026, and instead Rigetti entered 2026 Q2 with $541.3M cash and no debt, a major improvement from $92.6M cash/investments then. The roadmap also advanced from the 2024 target of an 84-qubit system and a 2025 target of 100+ qubits at 99.5% fidelity to today's generally available Cepheus-1-108Q and a stated 2026 goal of roughly 99.5% fidelity. The miss is on operating discipline: in 2024 Q3 CFO said, "I don't think we'll see a significant increase in OpEx going forward. So I would expect our OpEx to remain in line or slightly higher than what we've seen in the most recent quarters.", yet by 2026 Q2 operating loss had widened to $28.1M as R&D, infrastructure, and stock comp rose, and Q2 EBITDA still sat at -$0.05B. Earnings delivery versus Street has been better recently than in 2025, but the record is not clean, with 2 misses in the last 8 reports, including the latest -8.6% EPS miss on 2026-08-06.
Our objective remains to reach approximately 1,000 qubits, 2 qubit gate fidelities of 99.9% and gate speed below 40 nanoseconds in roughly 3 years.
In Q2, we continued to progress on the $8.4 million C-DAC order for an on-premises 108-quubit system in India, which we still expect to recognize in the fourth quarter of this year following installation and performance acceptance testing.
Near term, that means driving Cepheus-1-108Q toward a median 2-qubit gate fidelity of approximately 99.5% later this year while maintaining our gate speed advantages.
For the second quarter of 2026, revenue was approximately $5.1 million compared to $1.8 million in the second quarter of 2025. The year-over-year increase was driven by on-premises Novera QPU sales, reflecting recognition of previously announced Novera purchase orders.
We definitely expect more funding coming into the overall quantum computing ecosystem from the U.S. government because of those executive orders.
Rigetti's moat is real but narrow. It owns a full-stack superconducting quantum stack, including chip design, fabrication through Fab-1, control infrastructure, and system integration, which matters because quantum performance depends on co-optimizing all of those layers. Durability is still limited because larger-capitalized peers can fund similar roadmaps, and the decisive moat 3 to 5 years out will be measured by delivered fidelities, uptime, and customer-installed systems rather than by roadmap slides.
Capital allocation is currently about survival and technical scale-up, not shareholder yield. Buybacks and dividends are $0.0B, while 2026 CapEx is elevated versus prior years to fund Fab-1 and dilution refrigeration needed for the 1,000-qubit roadmap. That is strategically sensible given $541.3M cash and no debt, but investors should assume cash is being spent into R&D and infrastructure with uncertain near-term payback.
RGTI rates a SELL. The company has enough cash to keep building, and it may post a better Q4 if the $8.4M C-DAC system lands on time, but that does not change the central issue that the stock is priced for a far more mature business than the financials show today. The quant framework's $15.26 target already says upside is negligible from $14.93. A rating change would require either sustained proof of commercial revenue scaling beyond one-off system deliveries, or a materially lower stock price that better compensates for the execution gap between roadmap ambition and earnings reality.
≣ Full research note tap to expand
Executive Summary
SELL, High conviction. Rated SELL, High conviction. Rigetti has real technical progress, a strong cash cushion, and visible Q4 revenue from the $8.4M C-DAC delivery, but the stock still embeds years of success despite FY2025 revenue down 27.0%, operating margin at -798.7%, and a business model that is still dependent on lumpy system sales and non-definitive government funding. At $14.93, the market is paying for a future quantum leader today, while the quant engine's $15.26 target already implies only 2.2% upside.
Investment Thesis
The market is still capitalizing Rigetti as if technical progress will convert into durable commercial revenue on a fairly short path. The actual numbers do not support that view yet. FY2025 revenue was down 27.0%, EPS was -0.70, and operating margin worsened to -798.7%. Even after a better Q2, the company produced only $5.1M of revenue and -$0.05B of EBITDA. That is not a scaling software business with latent margin, it is a hardware and research-intensive platform still searching for repeatable commercial demand.
The bullish case is not hard to see. Rigetti has $541.3M of cash, virtually no debt, improving gross margin at 43%, an expected $8.4M Q4 system revenue event, and a credible technical roadmap centered on 108 qubits now and 1,000 qubits in roughly 3 years. Those are meaningful milestones. But the stock at $4.7B already assumes that roadmap turns into a much larger installed base, stronger utilization, and eventually software or services leverage. That leap has not happened. Revenue is still described by management as lumpy, tied to installations, government projects, and acceptance testing. Investors are paying today for a business model that is still mostly aspirational.
The key debate is not whether Rigetti survives. It probably does, given the cash balance and no-debt structure. The debate is whether the equity value leaves room for error. At 390.78x sales versus peer average 2.6x, it plainly does not. The Department of Commerce opportunity for up to $100M over 3 years could help, but it is non-definitive and would include equity issuance. That is support for the balance sheet and roadmap, not proof of attractive shareholder returns from this price.
Conviction is high because the setup is asymmetric in the wrong direction for new buyers. The stock is already -73.5% from its $56.34 high and 23.2% below the 200-day average of $19.44, which means plenty of air has come out, but not enough relative to fundamentals. A more durable long case would require one of two things: sustained annual revenue growth large enough to make today's market cap defensible, or a materially lower share price that better reflects pre-profit, milestone-driven commercialization risk.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $14.93 | Reference price for rating and scenario framework | ||
| Quant price target | $15.26 | High confidence, 2.2% above current, basis: sales_quality_blend | ||
| Market cap | $4.7B | Large equity value relative to current revenue base | ||
| FY2025 revenue | $0.0B | -27.0% YoY, still subscale on disclosed annual basis | ||
| FY2025 EPS | -$0.70 | Loss-making, 44.7% YoY | ||
| FY2025 operating margin | -798.7% | Worsened from -634.9% prior FY | ||
| Valuation | P/S 390.78x | P/B 9.71x | P/E N/A | P/S far above peer average 2.6x, peer avg P/E 24.8x |
| Balance sheet | Debt/Equity 0.01 | Current ratio 3.94 | Total debt $0.0B | Very strong liquidity, minimal leverage |
| Q2 2026 revenue and margin | $5.1M revenue | 43% gross margin | Up from $1.8M and 31% y/y, helped by Novera QPU sales | |
| Q2 2026 EBITDA | -$0.05B | Implied EBITDA margin -1023.9% | ||
| Cash and runway | $541.3M cash | No debt, supports elevated 2026 CapEx and roadmap execution | ||
| Price action | -11.87% 1W | -31.42% 3M | -73.5% vs 52-week high | Now 23.2% below 200-day average of $19.44 |
Financial Strength
The balance sheet is the best part of the story. $541.3M cash, total debt of $0.0B, debt/equity of 0.01, and a 3.94 current ratio mean the company can fund elevated 2026 investment without immediate refinancing pressure. That matters because the business is still deeply cash consumptive and margin-negative. The problem is not solvency, it is conversion: gross margin improved to 43% in Q2, but operating structure remains far too heavy relative to revenue, and there is still no evidence that near-term scale will absorb R&D and infrastructure spending fast enough to make earnings power visible.
Competitive Position
Rigetti's moat is real but narrow. It owns a full-stack superconducting quantum stack, including chip design, fabrication through Fab-1, control infrastructure, and system integration, which matters because quantum performance depends on co-optimizing all of those layers. Durability is still limited because larger-capitalized peers can fund similar roadmaps, and the decisive moat 3 to 5 years out will be measured by delivered fidelities, uptime, and customer-installed systems rather than by roadmap slides.
Management & Guidance
Management's near-term guide is concrete on one point and aspirational on the rest. The concrete item is CFO Jeffrey Bertelsen's statement: "In Q2, we continued to progress on the $8.4 million C-DAC order for an on-premises 108-qubit system in India, which we still expect to recognize in the fourth quarter of this year following installation and performance acceptance testing." The more strategic guidance is the 3-year roadmap to about 1,000 qubits, 99.9% 2-qubit fidelity, and gate speed below 40 ns, along with potential funding of up to $100M over 3 years. Credibility is fair, not strong: the company has broadly advanced technical milestones and strengthened liquidity, but expense control has been weaker than previously implied and the latest quarter included an EPS miss of 8.6%.
Segment Analysis
- Quantum systems and QPU product revenue (Not disclosed): Q2 2026 growth was driven by on-premises Novera QPU sales and recognition of previously announced purchase orders.
- Government and research contracts (Not disclosed): Revenue remains tied to milestone-based deliveries, with the $8.4M C-DAC system in India expected in Q4 2026 and the HPE/PSC 9-qubit system targeted for 2027.
- Geography (Not disclosed): International exposure is visible through the India C-DAC order, but the company does not provide a geographic revenue split in the supplied data.
Capital Allocation
Capital allocation is currently about survival and technical scale-up, not shareholder yield. Buybacks and dividends are $0.0B, while 2026 CapEx is elevated versus prior years to fund Fab-1 and dilution refrigeration needed for the 1,000-qubit roadmap. That is strategically sensible given $541.3M cash and no debt, but investors should assume cash is being spent into R&D and infrastructure with uncertain near-term payback.
Management Execution & Track Record
Execution has been mixed. On the positive side, management said in 2024 Q3 that liquidity should last until midway through Q1 2026, and instead Rigetti entered 2026 Q2 with $541.3M cash and no debt, a major improvement from $92.6M cash/investments then. The roadmap also advanced from the 2024 target of an 84-qubit system and a 2025 target of 100+ qubits at 99.5% fidelity to today's generally available Cepheus-1-108Q and a stated 2026 goal of roughly 99.5% fidelity. The miss is on operating discipline: in 2024 Q3 CFO said, "I don't think we'll see a significant increase in OpEx going forward. So I would expect our OpEx to remain in line or slightly higher than what we've seen in the most recent quarters.", yet by 2026 Q2 operating loss had widened to $28.1M as R&D, infrastructure, and stock comp rose, and Q2 EBITDA still sat at -$0.05B. Earnings delivery versus Street has been better recently than in 2025, but the record is not clean, with 2 misses in the last 8 reports, including the latest -8.6% EPS miss on 2026-08-06.
Positioning & Flows
Ownership is meaningful but not especially sticky, with the top 3 institutions holding 46.3% and insiders only 0.9%. Short interest is high at 18.00%, or 58,969,224 shares, though days-to-cover is only 1.4, which means squeeze risk exists but is less structurally powerful than the headline short figure suggests. Options positioning is in a negative gamma regime with zero-gamma at $15.62, which can amplify downside volatility if the stock remains below that level.
Bull Case
- $541.3M cash with debt/equity 0.01 gives Rigetti unusually strong runway for a pre-scale quantum company and sharply lowers financing stress near term.
- Q2 2026 revenue rose to $5.1M from $1.8M and gross margin improved to 43% from 31%, helped by Novera QPU sales and better contract mix.
- Management still expects to recognize the $8.4M C-DAC order in Q4 2026, and remains on track for 3 system deliveries in 2026, giving at least one concrete near-term revenue step-up.
- The roadmap remains ambitious but specific: Cepheus-1-108Q targeting roughly 99.5% 2-qubit gate fidelity later in 2026, then 1,000 qubits, 99.9% fidelity, and gate speed below 40 ns in roughly 3 years.
Bear Case
- FY2025 revenue was $0.0B, down 27.0% YoY, while the stock commands a $4.7B market cap and 390.78x sales, a mismatch that leaves little room for delay.
- Profitability moved the wrong way in FY2025, with operating margin at -798.7% versus -634.9% prior year and net margin at -1494.0%, showing scale benefits are still absent.
- Q2 EBITDA was -$0.05B on just $0.01B revenue, an EBITDA margin of -1023.9%, and operating loss widened to $28.1M as R&D, infrastructure, and stock comp increased.
- The most material outside funding lever is still uncertain: Department of Commerce support is only up to $100M over 3 years, remains non-definitive, and would include equity issuance.
Valuation & Price Target
Engine price target $15.26 (+2.2% vs current), High confidence.
- P/S Multiple: $0.05 (1% weight)
- Quality-adjusted: $15.65 (20% weight)
The quant baseline is HOLD with High conviction, and the engine's $15.26 target is only 2.2% above the current $14.93. The rating diverges to SELL because a near-flat target on a stock with 390.78x sales, -798.7% FY2025 operating margin, and -1023.9% Q2 EBITDA margin does not offer enough compensation for execution and valuation risk. The balance sheet is excellent, with $541.3M cash and no debt, and sell-side consensus is a low-signal Strong Buy from just 3 firms, but that does not offset the fact that fundamental monetization still lags the valuation by years rather than quarters.
Risk Assessment
Risk score 52/100 (Moderate). The biggest risk to the bearish call is that a combination of $8.4M Q4 delivery, additional 2027 system wins, and a definitive up to $100M government award causes investors to look through today's 390.78x sales valuation for longer than fundamentals justify.
The Bottom Line
RGTI rates a SELL. The company has enough cash to keep building, and it may post a better Q4 if the $8.4M C-DAC system lands on time, but that does not change the central issue that the stock is priced for a far more mature business than the financials show today. The quant framework's $15.26 target already says upside is negligible from $14.93. A rating change would require either sustained proof of commercial revenue scaling beyond one-off system deliveries, or a materially lower stock price that better compensates for the execution gap between roadmap ambition and earnings reality.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr